期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 86, 期 2, 页码 136-138出版社
WILEY
DOI: 10.1038/clpt.2009.97
关键词
-
Drug-independent models that link biomarker response to clinical end points are critical to support early (end of phase II) clinical decisions. In oncology, change in tumor size (a biomarker of drug effect evaluated in phase II) is linked to survival (a phase II end point) in some solid tumors. Change in tumor size can be used as a primary end point in the design and evaluation of phase II studies and in supporting go/no-go decisions and phase II study design.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据